StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.18 | $1.11 | -5.93% | 0.4M |
| 05-12 | $1.12 | $1.01 | -9.82% | 0.5M |
| 05-13 | $0.97 | $0.96 | -1.05% | 0.5M |
| 05-14 | $0.88 | $0.99 | +12.34% | 0.4M |
| 05-15 | $0.95 | $0.80 | -15.79% | 1.3M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for BFRI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for BFRI.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $10.08M | $41.70M | $24.61M | $17.62M |
Operating Income | $-4.32M | $-11.35M | $-15.91M | $-9.63M |
Net Income | $-4.75M | $-10.54M | $-16.18M | $-9.53M |
EPS (Diluted) | $-0.41 | $-1.04 | $-1.67 | $-1.05 |
Total Assets | $24.79M | $28.56M | $15.41M | $20.14M |
Total Liabilities | $18.72M | $18.08M | $18.00M | $24.81M |
Cash & Equivalents | $6.32M | $6.39M | $3.42M | $7.24M |
Free Cash Flow OCF − CapEx | $-75.00K | $-13.36M | $-10.99M | $-7.17M |
Shares Outstanding | 11.87M | 11.65M | 11.65M | 10.14M |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.